Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed.
Ketamine Wellness Centers Re-Opening? Delic Holdings Signs LOI with Peter/PetraMD
This week we got news that Ketamine Wellness Centers might have a renewed sign of life. Peter/PetraMD, the largest online provider of hormone therapy for men and women in the United States, has announced the intent to acquire Ketamine Wellness Centers.
“We understand telemedicine, and we understand what it is our patients want—they want to feel better, they want to get better, and they want to live better lives. This acquisition would definitely further our mission to provide affordable and equitable access to healthcare across the nation”
MindBio Therapeutics Receives Conditional Approval from the Canadian Securities Exchange for Listing
MindBio Therapeutics, a clinical-stage drug development company focused on microdosing research and trials, has announced its approval for listing on the CSE under the ticker symbol MBIO.
The company’s flagship program is a Phase 1 clinical trial for Microdosing LSD. Last year, MindBio completed its Phase 1 clinical trial, the largest safety study of its kind.
Beckley Psytech Launches Phase 2a study of 5-MeO-DMT for Alcohol Use Disorder
Beckley Psytech is moving its 5-MeO-DMT program forward, announcing a new Phase IIa study investigating its lead candidate, BPL-003, as a potential treatment for alcohol use disorder (AUD).
Beckley Psytech’s Phase IIa study, taking place at King’s College Hospital in London, will explore the safety, efficacy and pharmacokinetics of BPL-003 in patients diagnosed with alcohol use disorder (AUD).
MAPS Announces Positive Topline Results from Follow-Up Study
More good news from MAPS as it moves its trials through the final approval steps. These long-term follow-up result should only bolster their case to the FDA.
Amy Emerson, chief executive officer, MAPS PBC: “These results are consistent with previously published Phase 2 data demonstrating the sustained effect of MDMA-assisted therapy at least 12 months following treatment and suggest the acute treatment effect could last even longer.”
Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study
Algernon NeuroScience (AGN Neuro), has completed dosing of the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”). AGN Neuro also reports that the safety review committee has approved moving the study forward with the final cohort at an escalated dose after observing no safety or tolerability issues.
Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed